This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 566

Galectin Pays Stock Promoters to Entice Retail Investors

By Adam Feuerstein

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

12:34PM 07/28/14

Access to Horizon Pharma Drugs Cut By Two Leading PBMs

By Adam Feuerstein

Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.

10:56AM 07/28/14

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

By Adam Feuerstein

AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.

09:44AM 07/28/14

MannKind Afrezza Partnership News Coming Within Weeks

By Adam Feuerstein

MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.

11:30AM 07/25/14

Biotech Stock Mailbag: Intercept Pharma, Inovio

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07:31AM 07/25/14

The Story Behind Sarepta's Firing of its Top Scientist

By Adam Feuerstein

Sarepta terminates Chief Scientific Officer Art Krieg. Here's what I've learned about why he was fired.

09:21AM 07/24/14

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

By Adam Feuerstein

In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.

05:44PM 07/23/14

Puma Shares Soar When Wall Street Misplays Expectation Game

By Adam Feuerstein

Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.

12:26PM 07/23/14

Inovio Declares Spin-Laden Victory With DNA Vaccine

By Adam Feuerstein

Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.

10:17AM 07/23/14

Gilead Expected to Post Sky-High Hep C Sales in June Quarter

By Adam Feuerstein

The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.

12:12PM 07/22/14

« Back
Page 1 of 566

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs